CPT® Code 84235

1. Indications

The receptor assay coded under CPT® 84235 is indicated for the evaluation of tumors to determine their hormone receptor status, specifically for hormones other than estrogen or progesterone. This assay is performed in the following scenarios:

• Assessment of Tumor Response The assay is utilized to ascertain whether a tumor is likely to respond to hormone therapy based on the presence of specific endocrine receptors.
• Guiding Treatment Decisions The results of the assay help oncologists make informed decisions regarding the most effective treatment options for patients, particularly in cases where hormone therapy may be considered.
• Monitoring Tumor Characteristics The assay can be part of ongoing assessments to monitor changes in tumor characteristics over time, which may influence treatment strategies.

2. Procedure

The procedure for conducting a receptor assay under CPT® 84235 involves several critical steps to ensure accurate results. Each step is designed to isolate and analyze the tumor cells for the presence of specific hormone receptors.

• Step 1: Sample Collection A sample of tumor tissue is obtained, typically through a biopsy or surgical resection. This sample must be handled carefully to preserve the integrity of the cells for accurate testing.
• Step 2: Preparation of Tumor Cells The collected tumor tissue is processed in the laboratory to isolate the tumor cells. This may involve mechanical or enzymatic disaggregation to create a single-cell suspension suitable for analysis.
• Step 3: Receptor Binding Assay The isolated tumor cells are exposed to specific hormones that are being tested. The assay measures the binding of these hormones to the receptors on the tumor cells, indicating the presence or absence of hormone receptors.
• Step 4: Analysis and Interpretation The results of the binding assay are analyzed to determine the receptor status of the tumor. This information is then compiled into a report that details whether the tumor is receptor positive or negative for the hormone tested.

3. Post-Procedure

After the receptor assay is completed, the results are typically reviewed by the healthcare provider to determine the appropriate course of action. If the tumor is found to be receptor positive, hormone therapy may be recommended as part of the treatment plan. Conversely, if the tumor is receptor negative, alternative treatment options may be considered. It is essential for healthcare providers to discuss the results with the patient, including the implications for treatment and any potential next steps. Follow-up appointments may be scheduled to monitor the patient's response to therapy and to reassess the tumor characteristics as needed.